Navicixizumab (Anti-DLL4)

Catalog No.A2519       

       Clone No.

Print

Technical Data

CAS No. 1638338-43-8
Formulation 100mMPro-Ac,20mMArg-Ac,pH5.0
Isotype Human IgG2SA
Source CHO
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Biological Activity

Description Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.